Nanozyme Target Selectivity and Stability via Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Enzyme-based therapies in medicine face limitations such as lack of selectivity, antigenicity, and short effective life in the circulatory system, leading to significant side effects and poor stability during cell entry.
Innovation Solution
Development of nanozymes, which consist of nanoparticles, enzymes, and recognition moieties, designed to enhance selectivity, stability, and cellular uptake efficiency, allowing for targeted enzymatic activity without eliciting an immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural enzymes are used for therapeutic applications, then enzymatic activity is provided, but selectivity is poor leading to side effects
Solution Approach 1:
The enzyme system is segmented into two functional components: a recognition moiety that provides target selectivity and an enzyme moiety that provides catalytic activity. This segmentation allows the recognition moiety to specifically bind to disease-related targets while the enzyme acts only on bound substrates, eliminating off-target effects and improving selectivity without compromising enzymatic function.
Solution Approach 2:
The patent applies local quality by concentrating enzymatic activity only at locations where the recognition moiety binds to its target. The enzyme is delivered systemically but becomes locally activated only at the disease site through specific binding, creating high local selectivity while maintaining low systemic activity, thereby reducing side effects.
2Duration of action of stationary object
If enzymes are administered for prolonged treatment, then therapeutic effect is maintained, but immune response is elicited
Solution Approach 1:
The recognition moiety acts as an intermediary that mediates between the enzyme and the target. This intermediary component can be engineered to reduce immunogenicity while maintaining target specificity. The enzyme itself is protected from direct immune recognition by being conjugated to the recognition moiety, allowing prolonged therapeutic use without eliciting strong immune responses.
Solution Approach 2:
The patent creates a composite therapeutic agent combining the enzyme with a recognition moiety. This composite structure allows the enzyme to be delivered and maintained in the system for prolonged periods while the recognition moiety provides target-specific localization. The composite nature reduces immune recognition compared to free enzyme administration, enabling longer treatment durations.
3Adaptability or versatility
If enzymes are used in circulatory system, then systemic treatment is achieved, but effective life is short
Solution Approach 1:
The enzyme-recognition moiety conjugate performs self-service by automatically localizing to target tissues through specific binding. This self-targeting capability eliminates the need for complex delivery systems and allows the enzyme to remain in circulation longer, as it is protected by the recognition moiety and only becomes active at the target site, effectively extending its therapeutic life.
Solution Approach 2:
The recognition moiety provides multiple functions: it enables systemic circulation, provides target specificity, protects the enzyme from degradation, and directs local activation. This multi-functionality allows the enzyme to achieve both systemic distribution and extended effective life, as the recognition moiety shields the enzyme from proteolytic degradation while maintaining its catalytic activity.
4Ease of operation
If enzymes are administered for cell entry, then intracellular treatment is achieved, but stability is poor in endosome
Solution Approach 1:
The enzyme-recognition moiety conjugate performs preliminary action by binding to target receptors on the cell surface before endocytosis. This pre-binding ensures that the enzyme is selectively taken up into endosomes only at target cells, and the recognition moiety remains associated with the enzyme during endosomal transit, providing stability and preventing premature activation or degradation until the appropriate intracellular location is reached.
Data Source
AI summary
Embodiments of the present disclosure provides for nanozymes, methods of making nanozymes, methods of using nanozymes, and the like.